Key Details
Price
$50.80Annual ROE
-8.17%Beta
1.75Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum.
On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies.
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.
Where Will CRISPR Therapeutics Be in 3 Years?
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT.
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals.
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.
FAQ
- What is the primary business of CRISPR Therapeutics AG?
- What is the ticker symbol for CRISPR Therapeutics AG?
- Does CRISPR Therapeutics AG pay dividends?
- What sector is CRISPR Therapeutics AG in?
- What industry is CRISPR Therapeutics AG in?
- What country is CRISPR Therapeutics AG based in?
- When did CRISPR Therapeutics AG go public?
- Is CRISPR Therapeutics AG in the S&P 500?
- Is CRISPR Therapeutics AG in the NASDAQ 100?
- Is CRISPR Therapeutics AG in the Dow Jones?
- When was CRISPR Therapeutics AG's last earnings report?
- When does CRISPR Therapeutics AG report earnings?
- Should I buy CRISPR Therapeutics AG stock now?